Addentax Group (ATXG) Competitors

Addentax Group (NASDAQ:ATXG) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap multi-sector conglomerates companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.

Does the media prefer ATXG or BIAF?

In the previous week, Addentax Group and Addentax Group both had 1 articles in the media. bioAffinity Technologies' average media sentiment score of 0.70 beat Addentax Group's score of -0.12 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addentax Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, ATXG or BIAF?

Addentax Group has higher revenue and earnings than bioAffinity Technologies. Addentax Group is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addentax Group	$5.15M	0.59	-$3.11M	-$0.75	-0.94
bioAffinity Technologies	$2.53M	4.16	-$7.94M	-$0.82	-0.82

Which has more volatility and risk, ATXG or BIAF?

Addentax Group has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 2.98, suggesting that its share price is 198% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of ATXG or BIAF?

10.1% of Addentax Group shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 3.4% of Addentax Group shares are held by insiders. Comparatively, 35.1% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate ATXG or BIAF?

bioAffinity Technologies has a consensus target price of $6.00, indicating a potential upside of 788.89%. Given bioAffinity Technologies' stronger consensus rating and higher possible upside, analysts plainly believe bioAffinity Technologies is more favorable than Addentax Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addentax Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
bioAffinity Technologies	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ATXG or BIAF more profitable?

Addentax Group has a net margin of -74.33% compared to bioAffinity Technologies' net margin of -91.22%. Addentax Group's return on equity of -7.74% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addentax Group	-74.33%	-7.74%	-3.73%
bioAffinity Technologies	-91.22%	-205.09%	-115.95%

Does the MarketBeat Community believe in ATXG or BIAF?

bioAffinity Technologies received 1 more outperform votes than Addentax Group when rated by MarketBeat users. Likewise, 100.00% of users gave bioAffinity Technologies an outperform vote while only 0.00% of users gave Addentax Group an outperform vote.

Company	Underperform	Outperform
Addentax Group	Outperform Votes No Votes	Underperform Votes 1 100.00%
bioAffinity Technologies	Outperform Votes 1 100.00%	Underperform Votes No Votes

Summary

bioAffinity Technologies beats Addentax Group on 10 of the 17 factors compared between the two stocks.